Mesoblast Reports $21.9 Million Ryoncil Sales Revenue; Shares Up 8%

MT Newswires Live

2025/10/07

Mesoblast (ASX:MSB) reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, up 66% from the June quarter, according to a Tuesday Australian bourse filing.

Ryoncil is the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease, the filing added.

The company's shares rose nearly 8% in recent Tuesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573938547"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573938547\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573938547?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573938547","market":"hk","top_or_hot":-1,"title":"Mesoblast Reports $21.9 Million Ryoncil Sales Revenue; Shares Up 8%","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, up 66% from the June quarter, according to a Tuesday Australian bourse filing.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease, the filing added.</p><p>The company's shares rose nearly 8% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Reports $21.9 Million Ryoncil Sales Revenue; Shares Up 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Reports $21.9 Million Ryoncil Sales Revenue; Shares Up 8%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-07 09:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, up 66% from the June quarter, according to a Tuesday Australian bourse filing.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease, the filing added.</p><p>The company's shares rose nearly 8% in recent Tuesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2573938547","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573938547","pubTimestamp":1759801375,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, up 66% from the June quarter, according to a Tuesday Australian bourse filing.Ryoncil is the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease, the filing added.The company's shares rose nearly 8% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited"},"translate_title":"Mesoblast报告Ryoncil销售收入为2190万美元；股价上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5},"content_text":"Mesoblast (ASX:MSB) reported a gross revenue of $21.9 million on sales of its drug Ryoncil for the quarter ended Sept. 30, up 66% from the June quarter, according to a Tuesday Australian bourse filing.Ryoncil is the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease, the filing added.The company's shares rose nearly 8% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}